UCB SA (OTCMKTS:UCBJY) Short Interest Down 97.9% in January

UCB SA (OTCMKTS:UCBJY) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 100 shares, a decline of 97.9% from the December 31st total of 4,700 shares. Based on an average daily volume of 19,300 shares, the short-interest ratio is presently 0.0 days.

UCB Trading Down 1.6 %

OTCMKTS:UCBJY traded down $1.58 on Friday, reaching $97.18. The company’s stock had a trading volume of 26,891 shares, compared to its average volume of 24,078. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 12-month low of $46.00 and a 12-month high of $100.66. The stock has a 50 day moving average price of $97.60 and a 200 day moving average price of $92.36.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.